DAZZLE clinical trial : Kodiak Sciences doses first patients with KSI-301 in phase 3 wet AMD trial
October 15, 2019 No Comment
Kodiak Sciences said that it has treated the first patients in the phase 2 DAZZLE clinical trial of KSI-301, its investigational intravitreal anti-VEGF antibody biopolymer conjugate, in wet age-related macular degeneration (wet AMD). The DAZZLE trial (also called KSI-CL-102) is designed to assess the safety and efficacy of KSI-301 in AMD patients who are treatment-naïve. […]
Continue reading …
Agilent acquisition of BioTek : US-based lab instrument manufacturer Agilent Technologies has wrapped up its previously announced $1.16 billion acquisition of life science instrumentation manufacturer BioTek Instruments. The acquisition, which was announced in July 2019, is expected to boost Agilent’s position in the growing cell analysis segment. It was in 2015 when Agilent forayed into […]
Continue reading …
Graybug Vision has initiated the ALTISSIMO clinical trial, a phase 2b study, which will evaluate its pan-VEGF receptor inhibitor GB-102 in patients with wet age-related macular degeneration (wet AMD). Based in California, Graybug Vision is a clinical-stage pharma company engaged in developing drugs for ocular diseases like wet AMD, diabetic macular edema (DME), primary open […]
Continue reading …
Amphivena Therapeutics funding round : Amphivena Therapeutics has raised $62 million in a Series C financing round to expand the clinical development of its lead candidate AMV564 into solid tumors and also to develop its T cell engagement portfolio. Based in California, Amphivena Therapeutics is a clinical-stage immuno-oncology company focused on developing T cell engager […]
Continue reading …Annexon gets FDA fast track status for ANX005 in Guillain-Barré Syndrome
September 24, 2019 No Comment
Annexon Biosciences has bagged the fast track designation for its C1q inhibitor ANX005 from the US Food and Drug Administration (FDA) for the treatment of Guillain-Barré Syndrome (GBS). Considered to be a rare, acute, antibody-mediated autoimmune disease, Guillain-Barré Syndrome affects the peripheral nervous system for which there are no approved therapies in the US till […]
Continue reading …Cutera truSculpt iD body sculpting treatment gets expanded approval in Canada
September 16, 2019 No Comment
Cutera said that Health Canada has expanded approval for its truSculpt iD body sculpting treatment to cover its use for the reduction of circumference of the abdomen and non-invasive lipolysis, which is the permanent removal of fat cells from the body. According to American Society for Aesthetic Plastic Surgery and Medical Insight (MII), noninvasive body sculpting […]
Continue reading …
Aytu acquisition of Innovus : Colorado-based specialty pharma company Aytu BioScience has agreed to acquire Innovus Pharmaceuticals in a deal worth up to $24 million, as per the latest pharma acquisition news. Headquartered in California, Innovus Pharmaceuticals is an over the counter (OTC) consumer goods and specialty pharmaceutical company. On the other hand, Aytu BioScience […]
Continue reading …BioMed, University of California open cancer research center in San Diego
September 7, 2019 No Comment
The University of California San Diego (UC San Diego) and BioMed Realty have opened the Center for Novel Therapeutics (CNT) – a new cancer research center at the former’s Science Research Park in San Diego, California. The cancer research center in San Diego, which spans 137,500sft, has been developed with an investment of $92 million […]
Continue reading …
Neuropore Therapies has secured orphan drug designation for NPT520-34 from the US Food and Drug Administration (FDA) for the treatment of amyotrophic lateral sclerosis (ALS). The California-based biopharma company said that the orphan drug designation will enable the development of NPT520-34 in the treatment of the debilitating medical condition for which there are not many […]
Continue reading …
AtriCure acquisition of SentreHEART : Afib device manufacturer AtriCure has agreed to acquire California-based medical device company SentreHEART in a deal worth up to about $300 million. Based in Ohio, AtriCure makes devices for the treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management. AtriCure’s Isolator Synergy Ablation System is the first and […]
Continue reading …
Business News Today
- Nationwide, Generali to create N2G Worldwide Insurance Services JV
- Manna Tree Partners invests in organic beef producer Verde Farms
- Pernod Ricard rolls out caviar-infused vodka – L’Orbe Vodka x Caviar
- Skogul oil field : Aker BP set to begin production from Norwegian oil field
- COSMIC-311 clinical trial : Exelixis enrolls patients to study cabozantinib in phase 3 thyroid cancer trial
- Cystic fibrosis drug KALYDECO to be launched in New Zealand by Vertex Pharmaceuticals
- Sara Lee Frozen Bakery to acquire Cyrus O’Leary’s Pies
- Hexion to sell paint manufacturing plant in Yumbo, Colombia
- Essence Healthcare to acquire Mutual of Omaha’s Medicare Advantage business
- PepsiCo to acquire Chinese snack brand Be & Cheery for $705m
